β-Nicotinamide mononucleotide

• UNSPSC Description:

  β-nicotinamide mononucleotide (β-NM) is a product of the nicotinamide phosphoribosyltransferase (NAMPT) reaction and a key NAD+ intermediate. The pharmacological activities of β-nicotinamide mononucleotide include its role in cellular biochemical functions, cardioprotection, diabetes, Alzheimer's disease, and complications associated with obesity[1].

• Target Antigen:

  Endogenous Metabolite

• Type:

  Natural Products

• Related Pathways:

  Metabolic Enzyme/Protease

• Field of Research:

  Cancer; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/_beta_-Nicotinamide-mononucleotide.html

• Purity:

  99.90

• Solubility:

  H2O : 83.33 mg/mL (ultrasonic)

• Smiles:

  O[C@H]1[C@@H](O)[C@H]([N+]2=CC=CC(C(N)=O)=C2)O[C@@H]1COP(O)([O-])=O

• Molecular Weight:

  334.221

• References & Citations:

  [1]Poddar SK, et al. Nicotinamide Mononucleotide: Exploration of Diverse Therapeutic Applications of a Potential Molecule. Biomolecules. 2019;9(1):34. Published 2019 Jan 21.|[2]Lv H, et al. NAD+ Metabolism Maintains Inducible PD-L1 Expression to Drive Tumor Immune Evasion [published online ahead of print, 2020 Nov 3]. Cell Metab. 2020;S1550-4131(20)30554-4.|[3]Li J, et al. p53 prevents doxorubicin cardiotoxicity independently of its prototypical tumor suppressor activities. Proc Natl Acad Sci U S A. 2019;116(39):19626-19634.|[4]Yoshino J, et al Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 2011;14(4):528-536.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, protect from light)

• Clinical Information:

  No Development Reported

• CAS Number:

  1094-61-7